Literature DB >> 26062557

Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity.

Fang Xie1, Alice B Ke1, Gary D Bowers1, Maciej J Zamek-Gliszczynski2.   

Abstract

Blood cells are considered an important distributional compartment for metformin based on the high blood-to-plasma partition ratio (B/P) in humans (>10 at Cmin). However, literature reports of metformin's intrinsic in vitro B/P values are lacking. At present, the extent and rate of metformin cellular partitioning was determined in incubations of fresh human and rat blood with [(14)C]metformin for up to 1 week at concentrations spanning steady-state plasma Cmin, Cmax, and a concentration associated with lactic acidosis. The results showed that metformin's intrinsic equilibrium B/P was ∼0.8-1.4 in blood, which is <10% of the reported clinical value. Kinetics of metformin partitioning into human blood cells and repartitioning back into plasma were slow (repartitioning half-life ∼32-39 hours). These data, along with in vivo rapid and efficient renal clearance of plasma metformin (plasma renal extraction ratio ∼90%-100%), explain why the clinical terminal half-life of metformin in plasma (6 hours) is 3- to 4-fold shorter than the half-life in whole blood (18 hours) and erythrocytes (23 hours). The rate constant for metformin repartitioning from blood cells to plasma (∼0.02 h(-1)) is far slower than the clinical renal elimination rate constant (0.3 h(-1)). Blood distributional rate constants were incorporated into a metformin physiologically-based pharmacokinetic model, which predicted the differential elimination half-life in plasma and blood. The present study demonstrates that the extent of cellular drug partitioning in blood observed in a dynamic in vivo system may be very different from the static in vitro values when repartitioning from blood cells is far slower than clearance of drug in plasma.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26062557     DOI: 10.1124/jpet.115.225698

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury.

Authors:  Paolo Greco; Giuseppe Regolisti; Umberto Maggiore; Elena Ferioli; Filippo Fani; Carlo Locatelli; Elisabetta Parenti; Caterina Maccari; Ilaria Gandolfini; Enrico Fiaccadori
Journal:  J Nephrol       Date:  2018-12-06       Impact factor: 3.902

2.  Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.

Authors:  Jill C Chappell; P Kellie Turner; Y Anne Pak; James Bacon; Alan Y Chiang; Jane Royalty; Stephen D Hall; Palaniappan Kulanthaivel; Joseph V Bonventre
Journal:  Clin Pharmacol Ther       Date:  2018-12-30       Impact factor: 6.875

3.  Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine.

Authors:  Kotaro Nishiyama; Kota Toshimoto; Wooin Lee; Naoki Ishiguro; Bojan Bister; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-03-19

4.  Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species.

Authors:  Yoo-Seong Jeong; William J Jusko
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-07

5.  Comparison of the gamma-Pareto convolution with conventional methods of characterising metformin pharmacokinetics in dogs.

Authors:  Carl A Wesolowski; Surajith N Wanasundara; Paul S Babyn; Jane Alcorn
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-12-21       Impact factor: 2.745

6.  Metformin Transport Rates Between Plasma and Red Blood Cells in Humans.

Authors:  Janis Kurlovics; Darta Maija Zake; Linda Zaharenko; Kristaps Berzins; Janis Klovins; Egils Stalidzans
Journal:  Clin Pharmacokinet       Date:  2021-07-26       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.